Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CLLS logo CLLS
Upturn stock ratingUpturn stock rating
CLLS logo

Cellectis SA (CLLS)

Upturn stock ratingUpturn stock rating
$1.3
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

03/21/2025: CLLS (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -73.57%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 03/21/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 150.05M USD
Price to earnings Ratio -
1Y Target Price 5.8
Price to earnings Ratio -
1Y Target Price 5.8
Volume (30-day avg) 592888
Beta 3.28
52 Weeks Range 1.14 - 3.38
Updated Date 03/23/2025
52 Weeks Range 1.14 - 3.38
Updated Date 03/23/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.41

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-03-14
When -
Estimate -0.21
Actual -0.16

Profitability

Profit Margin -74.69%
Operating Margin (TTM) -70.43%

Management Effectiveness

Return on Assets (TTM) -10.37%
Return on Equity (TTM) -34.08%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -18251032
Price to Sales(TTM) 3.05
Enterprise Value -18251032
Price to Sales(TTM) 3.05
Enterprise Value to Revenue 3.74
Enterprise Value to EBITDA -3.9
Shares Outstanding 100094000
Shares Floating 38846342
Shares Outstanding 100094000
Shares Floating 38846342
Percent Insiders 3.87
Percent Institutions 20.71

Analyst Ratings

Rating 4.33
Target Price 6.67
Buy 2
Strong Buy 3
Buy 2
Strong Buy 3
Hold 1
Sell -
Strong Sell -
Strong Sell -

Upturn AI SWOT

Cellectis SA: A Comprehensive Overview

Company Profile:

History and Background:

Cellectis SA is a clinical-stage biopharmaceutical company pioneering the field of allogeneic CAR T-cell therapies. Founded in 1993 and headquartered in Paris, France, the company focuses on developing innovative therapies for cancer, autoimmune diseases, and other serious diseases.

Core Business Areas:

  1. Allogeneic CAR T-Cell Therapies: Cellectis develops engineered T cells that can recognize and attack cancer cells, with the potential for off-the-shelf availability.
  2. Universal CAR T Platform: The company's innovative platform technology allows for the creation of multiple CAR-T cell therapies targeting various blood cancers.
  3. Delivery Solutions: Cellectis researches and develops novel technologies for the efficient delivery of CAR-T cells to the patient's body.

Leadership Team:

Cellectis is led by CEO André Choulika, a visionary leader in the field of cellular therapy. The company boasts a strong management team with extensive expertise in biopharmaceutical research, development, and commercialization.

Top Products and Market Share:

  1. UCART19: A CAR T-cell therapy targeting CD19-positive B-cell malignancies, currently in Phase I/II clinical trials for the treatment of acute lymphoblastic leukemia (ALL).
  2. UCART123: Another CAR T-cell therapy targeting CD123 in acute myeloid leukemia (AML), currently undergoing Phase I clinical trials.

Market Share:

While Cellectis' products are still in development, the CAR-T cell therapy market is rapidly growing. The global market is expected to reach $12.7 billion by 2030, with significant growth potential in the US.

Competition:

Cellectis faces competition from several established players in the CAR-T therapy market, including Novartis (NVS), Gilead (GILD), and Bristol Myers Squibb (BMY). These companies have already launched CAR-T therapies for certain blood cancers.

Total Addressable Market:

The global CAR T-cell therapy market is estimated to reach $12.7 billion by 2030. The US market is projected to grow at an even faster pace, reaching $6.2 billion by 2030. This significant market size indicates the tremendous potential for companies like Cellectis in the coming years.

Financial Performance:

Cellectis is currently in the clinical development stage and does not generate significant revenue. The company's financials are primarily driven by research and development expenses. However, it is important to consider the company's cash runway and burn rate.

Dividends and Shareholder Returns:

Cellectis does not currently pay dividends as it focuses on investing in research and development. Shareholder return will depend heavily on the company's success in bringing its therapies to the market and achieving commercial success.

Growth Trajectory:

Cellectis has a promising growth trajectory based on the potential of its CAR-T cell therapies and the rapidly growing CAR-T market. The company has several ongoing clinical trials and expects to receive regulatory approval for its lead product, UCART19, by 2025.

Market Dynamics:

The CAR-T cell therapy market is characterized by rapid technological advancements, increasing approvals of new therapies, and growing demand from patients. However, high manufacturing costs, regulatory hurdles, and safety concerns pose challenges to the industry.

Competitive Advantages and Disadvantages:

Cellectis' competitive advantages include its proprietary CAR-T platform technology, strong intellectual property portfolio, and experienced leadership团队. However, the company's lack of approved therapies, limited commercial experience, and competition from larger players pose disadvantages.

Potential Challenges and Opportunities:

Cellectis faces challenges in navigating the complex regulatory landscape, maintaining a strong cash position, and competing with larger players. However, the company has opportunities to expand its product portfolio, enter new markets, and benefit from the growth of the CAR-T cell therapy market.

Recent Acquisitions (last 3 years):

Cellectis has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating:

Based on an AI analysis, Cellectis SA receives a fundamental rating of 6 out of 10. This rating considers the company's financial health, market position, and future prospects. The company has a solid intellectual property portfolio, strong technological foundation, and significant growth potential, but it faces challenges in terms of competition and cash runway.

Sources and Disclaimers:

Conclusion:

Cellectis SA is an innovative company with promising potential in the field of CAR-T cell therapy. Although the company faces challenges, its proprietary technology, strong management team, and large addressable market, suggest a promising future.

This report provides a comprehensive overview of the company's current state and future potential. It is essential to stay updated on the latest developments and consider the inherent risks associated with investing in a clinical-stage biopharmaceutical company.

About Cellectis SA

Exchange NASDAQ
Headquaters -
IPO Launch date 2007-02-07
Co-Founder, CEO & Director Dr. Andre Choulika Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 216
Full time employees 216

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​